No headlines found.
Globe Newswire (Thu, 9-Jul 4:05 PM ET)
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
Globe Newswire (Thu, 14-May 4:05 PM ET)
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
Globe Newswire (Thu, 7-May 4:05 PM ET)
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Immucell trades on the NASDAQ stock market under the symbol ICCC.
As of July 24, 2026, ICCC stock price climbed to $11.03 with 8,434 million shares trading.
ICCC has a beta of 0.94, meaning it tends to be less sensitive to market movements. ICCC has a correlation of 0.06 to the broad based SPY ETF.
ICCC has a market cap of $99.79 million. This is considered a Micro Cap stock.
In the last 3 years, ICCC traded as high as $12.10 and as low as $3.34.
The top ETF exchange traded funds that ICCC belongs to (by Net Assets): VTI, VXF, IWC, DFAT, DCOR.
ICCC has outperformed the market in the last year with a price return of +63.2% while the SPY ETF gained +17.7%. ICCC has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +32.0% and +1.3%, respectively, while the SPY returned +3.8% and -2.1%, respectively.
ICCC support price is $10.40 and resistance is $11.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ICCC shares will trade within this expected range on the day.